We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Woodford Patient Capital Trust Plc | LSE:WPCT | London | Ordinary Share | GB00BVG1CF25 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.60 | 33.55 | 33.90 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
15/6/2017 16:18 | May update (registration needed): Toffeeman - yes, he was in EveSleep before the IPO. Latest nav 100.2p. | jonwig | |
15/6/2017 14:00 | There are some holdings which are highly likely to IPO (AJ Bell springs to mind) in the not too distant future and indeed I would expect Woody to 'encourage' this (and others) to happen in order to make things look somewhat rosier. | toffeeman | |
15/6/2017 12:50 | I think that's right. There are many who attach importance to WPCT's 'current' NAV which, as the last two posters have pointed out, is futile. Quite honestly the only rationale for investing here is to have faith in Woodford and his crew to get it right over 4 or 5 years or more. That's not as stupid as it seems! | solonic | |
15/6/2017 09:27 | If a whole sector is sold off (like Biotech, say) an unquoted would be revalued to a lower PER (if it has earnings) or an appropriate percentage if it hasn't any. That wouldn't be done on a regular basis, though. Also, the fund will have up-to-date numbers on profit and turnover, so may adjust on that basis. If you invest in VCTs, you'll find they do this maybe twice a year. I'm actually surprised WPCT bothers to publish a daily NAV: it costs at least £250 to issue an RNS through the LSE (or it did, some years ago). | jonwig | |
15/6/2017 08:50 | Basically the only points at which unquoted companies are properly (or improperly :)) valued are fundraising rounds or IPO, when of course they become quoted! | toffeeman | |
14/6/2017 19:08 | timnet - not a whim. There are strict rules for valuing unquoted companies: Valuation guidelines, p11. | jonwig | |
14/6/2017 18:41 | Thanks, Toffeeman. When are unquoted valuations carried out? Is it to a set timetable (in which case NAVs might be relevent if we can factor that in) - or at the whim of the investment manager (when they wouldn't)? Do we know? Ta. | timnet | |
14/6/2017 12:32 | The NAV is irrelevant given the frequency of unquoted revaluations - so imo it's a meaningless metric here. | toffeeman | |
14/6/2017 11:57 | Why is it taking so long to get the daily NAV published? Not yet available yet today. Are the Board making valuations of unlisted investments? | timnet | |
15/5/2017 17:11 | Wouldn't say meaningless. I get what you mean - something is only worth what someone is willing to pay and we can't gauge that accurately (and some of the positions in the smaller quoted co's are so large they couldn't easily be sold). But its the only measure there is and it better it goes up rather than down... | dr biotech | |
15/5/2017 13:37 | Dr B (as I am sure you would agree) NAV is meaningless given the proportion of unquoted companies in the portfolio. Uq can only be valued at that prevailing at the previous round of fundraising. | toffeeman | |
15/5/2017 11:19 | NAV inches ahead of the starting line just over 100p. Hopefully not a false dawn | dr biotech | |
12/5/2017 18:12 | Thanks - yes seen that. I'm not tempted at this point in the cycle. 50p or lower for me. | topvest | |
11/5/2017 18:31 | topvest - this will be music to your ears, then: | jonwig | |
11/5/2017 18:14 | Patiently awaiting a larger discount and a bear market is the best way to go on this one. | topvest | |
11/5/2017 12:02 | Mind you, with the NAV now at over 98p, fortune may favour the impatient. | mad foetus | |
11/5/2017 11:47 | Just chill. Clue's in the name.. 'Patient' | wtacraig1 | |
09/5/2017 13:24 | Gentlemen - The key is how the unquoted coys are performing against their objectives As Dr B kindly points out one of the Unquoted has progressed and Phase 1 scheduled for warly 2018 - but Phase 1 is a long way from success in Phase 3. However if successful in phase 3 then potentially massive upside for the Trust to makw up for some of the current failures in quoted vehicles such as Allied Minds, RM2 etc. | pugugly | |
09/5/2017 11:16 | Wakey wakey! | rambutan2 | |
09/5/2017 10:31 | Some progress on one of the unquoted holding Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore. Based in Oxford, Immunocore is one of the hottest biotechs in the immuno-oncology space, which was able to raise one of the largest European private funding rounds ever (€300M) and is backed by several big pharma partners including Genentech and GlaxoSmithKline (GSK). Now, the British biotech has added a second lead compound to its discovery collaboration agreement with GSK, securing itself a new milestone payment. The two partners initiated their collaboration back in 2013 and GSK agreed to pay Immunocore a massive total of £142M (€170M) in potential pre-clinical milestone payments, adding up to £200M (€240M) in milestones — and double digit royalties — for each new therapy that makes it to the market. The pharma giant seems to be intrigued by Immunocore’s ImmTAC technology, which links a T cell receptor (TCR) with an anti-CD3 antibody to flag the cancer cells for T cell-mediated killing. In contrast to CAR T cells, the TCRs are able to recognize intracellular tumor antigens that are presented on the surface of the tumor cells, allowing for access to a much wider variety of targets. The anti-CD3 effector domain of the ImmTAC is able to bind and efficiently activate the T cell to kill the cancer cells bound by the TCR. According to Immunocore, the new ImmTAC candidate is relevant in a number of solid cancers including triple negative breast cancers, oesophageal, gastric and ovarian cancers, expanding the indications the company’s technology. The first ImmTAC program under Immunocore’s GSK collaboration is on track to be submitted as an IND this year and will enter Phase I clinical studies during early 2018, with potential application in Non-Small Cell Lung Cancer (NSCLC), bladder cancer, synovial sarcoma, melanoma and ovarian cancer. While the immuno-oncology space could not be more crowded right now, both investors and big pharma seem to be confident that Immunocore’s innovative technology bears high potential to tackle the challenging solid tumors. | dr biotech | |
02/5/2017 21:08 | He's distracted. | p1nkfish | |
02/5/2017 20:41 | Am a big Woodford fan and judge his performance over years rather than months,however it has to be said that over the last few years his performance on all his funds has been average at best. | tim 3 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions